Side effects of antimalarial drugs? These may be symptoms of a disease.

Quinism.

Side effects of antimalarial drugs?

These may be symptoms of a disease.

Quinism.

The Quinism Foundation is a 501(c)(3) nonprofit charitable organization established January 1, 2018 in White River Junction, Vermont.

The Quinism Foundation promotes and supports education and research on quinism, the medical disorder caused by poisoning by mefloquine, tafenoquine, chloroquine, and related quinoline drugs.

Symptoms of quinism (also known as chronic quinoline encephalopathy) can mimic those of several psychiatric and neurologic disorders including PTSD and TBI.

Looking for information related to the use of chloroquine, hydroxychloroquine, mefloquine, tafenoquine, and related quinolines in the COVID-19 pandemic?

Read this press release, and sign up for our mailing list to be kept informed

Join our mailing list for regular updates

The term “quinism” may seem new, but the symptoms of poisoning by mefloquine (previously marketed as Lariam®), tafenoquine (marketed as Krintafel® and Arakoda™), chloroquine (marketed as Aralen®), and related quinoline drugs are all too familiar: Tinnitus. Dizziness. Vertigo. Paresthesias. Visual disturbances. Gastroesophageal and intestinal problems. Nightmares. Insomnia. Sleep apnea. Anxiety. Agoraphobia. Paranoia. Cognitive dysfunction. Depression. Personality change. Suicidal thoughts.

These symptoms are not “side effects”. They are symptoms of poisoning by a class of drug that is neurotoxic and that injures the brain and brainstem. This poisoning causes a disease, and this disease has a name: Chronic quinoline encephalopathy — also known as quinism.

Recent Press Releases

Recent Newsletters

April 8, 2020

FDA Approves Chloroquine and Hydroxychloroquine for Emergency Use Against COVID-19; Online Annual Meeting Update; Russian Mefloquine Disinformation?

March 16, 2020

Ask Your Senator To Support Research on Quinism; VA Awards Another 100% Mefloquine Rating; GSK Asks for Krintafel® Label Change; Annual Meeting Update